Ayvakit (avapritinib)

avapritinib · Blueprint Medicines Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ayvakit (avapritinib), covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis [Phase 2]

See pricing